Yale researchers have tested a new method for directly measuring synaptic loss in individuals with Alzheimer's disease. The method, which uses PET imaging technology to scan for a specific protein in the brain linked to synapses, has the potential to accelerate research for new Alzheimer's treatments, the researchers said.
Arranging into well-organized fibrillar aggregate, commonly known as amyloid fibril is an inherent property of any polypeptide chain. Amyloid fibrils are associated with a number of severe human pathologies like the Alzheimer's disease, Parkinson's disease, type 2 diabetes and many more. This review article includes the recent studies of identification and characterization of possible conformations of proteins which can act as aggregation precursor state (APS).
A new way to examine stress and inflammation in the heart will help Parkinson's researchers test new therapies and explore an unappreciated way the disease puts people at risk of falls and hospitalization.
Contact with greenspace is known to have beneficial effects for mental health. A new study by the Barcelona Institute for Global Health (ISGlobal) suggests that it may also play a positive role against cognitive decline in elderly. In particular, this research published in Environmental Health Perspectives shows that the loss in cognitive functions expected as part of the aging process is slightly slower in people who live in greener neighborhoods.
New research from South Australian scientists has shown that vitamin D (also commonly known as the sunshine vitamin) is unlikely to protect individuals from multiple sclerosis, Parkinson's disease, Alzheimer's disease or other brain-related disorders.
Parkinson's disease was first described by a British doctor more than 200 years' ago. The exact causes of this neurodegenerative disease are still unknown. In a study recently published in eLife, a team of researchers led by Professor Henning Stahlberg from the Biozentrum of the University of Basel has now questioned the previous understanding of this disease.
By combining ultrasound, gene therapy, and synthetic drugs, researchers have figured out a way to noninvasively control the brain.
A new technique for precisely targeting molecules within cells is paving the way for safer medicines that are free of side effects. Big benefits are expected in the battle against cancer, autism, Alzheimer's and more.
Researchers at TGen and Circuit Therapeutics Inc. are studying the brain's striatum, which not only is responsible for controlling how we move, but also contributes to the brain's decision-making and the initiation of action. Nearly 95 percent of the cells that make up the striatum are known as medium spiny neurons (MSN), which is associated with many psychiatric and neurodegenerative diseases, including Parkinson's disease, Huntington's disease, schizophrenia, drug addition and ADHD.
Targeting multiple proteins at once may be the real key to treating neurodegenerative diseases, according to a recent study published in Brain by Penn Medicine researchers.